In contrast, a recent study reported that the levels of some subtypes of EPCs (CD34+/CD133+/CD34+CD133+/CD34+KDR+) were reduced in newly diagnosed T2DM patients and did not vary after intensive insulin therapy; however, a pool of EPCs (CD34+KDR+CD133+) was increased in these patients and decreased after intensive insulin therapy, with a simultaneous reduction in oxidative stress and inflammation [164]. The gene discussed is CD34; the disease is type 2 diabetes mellitus.